CEO, Vaxxas
Stories naming David Peacock. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A fund's insights listing: its headline flags Vaxxas naming an ex-Merck vaccines chief as CEO, while linked teasers report Eucalyptus' $1.6b sale and Accel-KKR's takeover of Phocas.
Curated OneVentures roundup: Eucalyptus sold to a New York-listed healthcare group for $1.6 billion and Vaxxas named ex-Merck vaccines president David Peacock as CEO, plus patent-cliff and women-in-tech links.
OneVentures' insights feed highlights a pharma patent-cliff analysis, an AFR feature, Eucalyptus' $1.6b sale to a US healthcare group, and Vaxxas naming David Peacock chief executive.
OneVentures insights listing linking to coverage of Eucalyptus's $1.6b sale to a US-listed healthcare company and Vaxxas hiring a former Merck vaccines president as CEO.
Publisher's post about a venture firm multiplying its money thirteen-fold on one startup bet; the page also carries linked reports of Eucalyptus's $1.6 billion sale and Vaxxas naming David Peacock chief executive.
A OneVentures post reports a needle-free vaccine developer raising A$34 million; linked items on the page note Eucalyptus's $1.6 billion sale to a US-listed healthcare firm and Vaxxas naming David Peacock chief executive.
Also Blackbird Ventures portfolio·Startup Daily·SmartCompany·Dealroom·SmartCompany·Startup Daily·Dealroom·Forbes Australia